Astrazeneca (AZN) Cash from Investing Activities (2009 - 2026)

Astrazeneca's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$1.8 billion for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 43.02% year-over-year to -$1.8 billion; the TTM figure through Mar 2026 stood at -$7.3 billion (down 7.73% YoY), while the FY2025 annual figure was -$6.8 billion, up 14.69% from the prior year.
• Cash from Investing Activities was -$1.8 billion for Q1 2026 at Astrazeneca, down from -$1.4 billion in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$168.0 million in Q1 2022 to a low of -$2.9 billion in Q2 2024.
• Historically, Cash from Investing Activities has averaged -$1.5 billion across 5 years, with a median of -$1.4 billion in 2025.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities slumped 641.67% in 2023, then jumped 48.07% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$800.0 million in 2022, then surged by 35.0% to -$520.0 million in 2023, then slumped by 127.12% to -$1.2 billion in 2024, then declined by 22.44% to -$1.4 billion in 2025, then declined by 23.93% to -$1.8 billion in 2026.
• The last three Cash from Investing Activities figures came in at -$1.8 billion (Q1 2026), -$1.4 billion (Q4 2025), and -$2.0 billion (Q3 2025), per Business Quant data.